bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Blood

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood.v82.6.1820.1820PMID 8104532
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line.

  1993cited by this paper
• bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs.

  1992cited by this paper
• Bcl-2 initiates a new category of oncogenes: regulators of cell death.

  1992cited by this paper
• Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells.

  1992cited by this paper
• bcl-2 gene expression in hematopoietic cell differentiation.

  1992cited by this paper
• Cooperative interaction between c-myc and bcl-2 proto-oncogenes

  1992cited by this paper
• Differential effects of Bcl-2 on T and B cells in transgenic mice.

  1992cited by this paper
• Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia.

  1992cited by this paper
• Cell cycle analysis of p26-BCL-2 protein levels in proliferating lymphoma and leukemia cell lines.

  1992cited by this paper
• Immunolocalization of the Bcl-2 protein within hematopoietic neoplasms.

  1991cited by this paper
• Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18)

  1991cited by this paper
• Oncogene rearrangements in chronic B-cell leukemia.

  1991cited by this paper
• Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin.

  1991cited by this paper
• B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL.

  1991cited by this paper
• Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma.

  1991cited by this paper
• Enhanced detection of the t(14;18) translocation in malignant lymphoma using pulsed-field gel electrophoresis.

  1991cited by this paper
• bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes.

  1991cited by this paper
• Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years.

  1991cited by this paper
• Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death.

  1991cited by this paper
• Meiotic recombination between yeast artificial chromosomes yields a single clone containing the entire BCL2 protooncogene.

  1990cited by this paper
• Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia

  1990cited by this paper
• Chronic lymphocytic leukemia: new insights into biology and therapy.

  1990cited by this paper
• The human minisatellite consensus at breakpoints of oncogene translocations.

  1990cited by this paper
• Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation.

  1990cited by this paper
• Regulation of bcl-2 gene expression in lymphoid cell lines containing normal #18 or t(14;18) chromosomes.

  1989cited by this paper
• bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation.

  1989cited by this paper
• A search for bcl1, bcl2, and c-myc oncogene rearrangements in chronic lymphocytic leukemia.

  1989cited by this paper
• Variant translocation of the bcl-2 gene to immunoglobulin lambda light chain gene in chronic lymphocytic leukemia.

  1989influential reference
• Pre-B-cell leukemia with a t(8; 14) and a t(14; 18) translocation is preceded by follicular lymphoma.

  1988cited by this paper
• 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia.

  1988cited by this paper
• The reciprocal partners of both the t(14; 18) and the t(11; 14) translocations involved in B-cell neoplasms are rearranged by the same mechanism.

  1988cited by this paper
• Alternative promoters and exons, somatic mutation and deregulation of the Bcl‐2‐Ig fusion gene in lymphoma.

  1988cited by this paper
• Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma.

  1988cited by this paper
• Promoter inhibition by DNA methylation: a reversible signal.

  1988cited by this paper
• Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells.

  1987cited by this paper
• Characterization of translocation contact sites involved in the import of mitochondrial proteins

  1987cited by this paper
• Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma.

  1986cited by this paper
• Expression of the T1 (CD5, p67) surface antigen in B‐CLL and B‐NHL and its correlation with other B‐cell differentiation markers

  1986cited by this paper
• Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas

  1986cited by this paper
• Involvement of the bcl-2 gene in human follicular lymphoma.

  1985cited by this paper
• Regulation of c-myc mRNA levels in normal human lymphocytes by modulators of cell proliferation.

  1985influential reference
• Transcription of the mammalian mitochondrial genome.

  1984cited by this paper
• The natural history of initially untreated low-grade non-Hodgkin's lymphomas.

  1984cited by this paper
• Clinical patterns in B lymphoid malignancy.

  1982cited by this paper
• Cell death: the significance of apoptosis.

  1980cited by this paper

• Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia

  2025cites this paper
• Inhibition of NEDDylation enhances the cytostatic effect of Rohinitib on chronic lymphocytic leukemia cells.

  2025cites this paper
• Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia.

  2025cites this paper
• Synthesis and Biological Evaluation of Quercetagetin Derivatives as the Inhibitors of Mcl-1 and Bcl-2 Against Leukemia

  2025cites this paper
• A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies.

  2025cites this paper
• Targeting the YY1-Bcl2-c-Myc Axis in the treatment of non-Hodgkin lymphoma.

  2025cites this paper
• Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins

  2025cites this paper
• Monitoring Response and Resistance to Treatment in Chronic Lymphocytic Leukemia

  2024cites this paper
• Association of MTHFR gene polymorphisms with non-Hodgkin lymphoma risk: Evidence from 31 articles

  2024cites this paper
• Immunogenic Cell Death Traits Emitted from Chronic Lymphocytic Leukemia Cells Following Treatment with a Novel Anti-Cancer Agent, SpiD3

  2024cites this paper
• Decoding the Tumour Microenvironment: Molecular Players, Pathways, and Therapeutic Targets in Cancer Treatment

  2024cites this paper
• BCL2i-Based Therapies and Emerging Resistance in Chronic Lymphocytic Leukemia

  2024cites this paper
• The role of aberrant DNA methylation in cancer initiation and clinical impacts

  2024cites this paper
• Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.

  2024cites this paper
• The Role of Methylation in Chronic Lymphocytic Leukemia and Its Prognostic and Therapeutic Impacts in the Disease: A Systematic Review

  2024cites this paper
• Biomarker-directed therapy in multiple myeloma

  2024cites this paper
• A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol

  2024cites this paper
• BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism

  2024cites this paper
• Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-xL/Bcl-w Inhibitors

  2024cites this paper
• BCL-2 inhibition in haematological malignancies: Clinical application and complications.

  2024cites this paper
• BCL2 G quadruplex-binding small molecules: current status and prospects for the development of next-generation anticancer therapeutics.

  2022cites this paper
• DNA Methylation: From Cancer Biology to Clinical Perspectives.

  2022cites this paper
• BCL-2 protein family: attractive targets for cancer therapy

  2022cites this paper
• The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine

  2022cites this paper
• BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion

  2022cites this paper
• Epitope Detection in Monocytes (EDIM) As a New Method of Liquid Biopsy in Pediatric Rhabdomyosarcoma

  2022cites this paper
• Proteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia

  2021cites this paper
• Research advances on epigenetics and cancer metabolism.

  2021influential citation
• TAp63 and BCL2 expression are co-affected by cell-extrinsic signals in chronic lymphocytic leukemia

  2021cites this paper
• Integrating New Therapies for Chronic Lymphocytic Leukemia

  2021cites this paper
• Proteomic approaches reveal the deregulation of Apoptotic proteins in MCF7 breast cancer cell line treated byred seaweed, Gracilaria corticota

  2021cites this paper
• Extrinsic Interactions in the Microenvironment In Vivo Activate an Antiapoptotic Multidrug-Resistant Phenotype in CLL.

  2021cites this paper
• Venetoclax as a therapeutic option for the treatment of chronic lymphocytic leukemia: the evidence so far

  2021cites this paper
• DNA Methylation-Mediated Low Expression of CFTR Stimulates the Progression of Lung Adenocarcinoma

  2021cites this paper
• Challenges in small-molecule target identification: a commentary on “BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models”

  2021cites this paper
• Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?

  2021cites this paper
• Breast Cancer and Smell: Hints from Epigenetic and Functional Alteration of the Olfaction

  2021cites this paper
• Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer

  2021influential citation
• Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review

  2021cites this paper
• Targeting epigenetic mechanisms to overcome venetoclax resistance.

  2021cites this paper
• CRISPR/Cas9 in epigenetics studies of health and disease.

  2021cites this paper
• Telomerase Regulation: A Role for Epigenetics

  2021cites this paper
• Immunohistochemical Characterization of Bcl-2 in Oral Potentially Malignant Disorders.

  2021cites this paper
• CMAR_A_283903 1459..1476

  2021cites this paper
• Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived

  2020cites this paper
• An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy

  2020cites this paper
• Apoptotic effect of berberine via Bcl‐2, ROR1, and mir‐21 in patients with B‐chronic lymphocytic leukemia

  2020cites this paper
• Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months.

  2020cites this paper
• Integrated analysis of DNA methylation and mRNA expression profiles to identify key genes in head and neck squamous cell carcinoma

  2020cites this paper
• Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm

  2020cites this paper
• Bcl-2 chromosomal translocation t(14;18) in lung cancer tumors and lung biopsy specimens.

  2020cites this paper
• The Mitochondrial Proteome of Tumor Cells: A SnapShot on Methodological Approaches and New Biomarkers

  2020cites this paper
• Regulation of DNA methylation machinery by epi-miRNAs in human cancer: emerging new targets in cancer therapy

  2020cites this paper
• Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia

  2020cites this paper
• BCL-XL inhibition by BH3-mimetic drugs induces apoptosis in models of Epstein-Barr virus-associated T/NK-cell lymphoma.

  2020cites this paper
• CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma

  2020cites this paper
• SOHO State of the Art Updates and Next Questions: Clonal Evolution in Chronic Lymphocytic Leukemia.

  2020cites this paper
• Epigenetic mechanisms and the hallmarks of cancer: an intimate affair.

  2020cites this paper
• Bicelin (B-cell lymphoma 2 inhibitor) a Highly Safe DNA-based Anti-cancer Drug Showed No in vivo Cytopenia, Nephrotoxicity and/or Hepatotoxicity

  2020cites this paper
• Bcl-2 family proteins, beyond the veil.

  2020cites this paper
• BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas

  2020cites this paper
• Cell plasticity in cancer: A complex interplay of genetic, epigenetic mechanisms and tumor micro-environment.

  2020cites this paper
• Mitochondrial microRNA (MitomiRs) in cancer and complex mitochondrial diseases: current status and future perspectives

  2020cites this paper
• Shedding Light on the Interaction of Human Anti-Apoptotic Bcl-2 Protein with Ligands through Biophysical and in Silico Studies

  2019cites this paper
• 1-1-2019 Targeting the Bcl-2 Family in B Cell Lymphoma

  2019cites this paper
• Neue Therapiemöglichkeiten für Patienten mit CLL

  2019cites this paper
• From Biology to Therapy: The CLL Success Story

  2019cites this paper
• Is venetoclax a new wonder drug in CLL?

  2019cites this paper
• Biomarkers for the Early Detection of Cervical Cancer

  2019cites this paper
• Apoptosis in Cancer Cell Signaling and Current Therapeutic Possibilities

  2019cites this paper
• Apoptotic resistance in chronic lymphocytic leukemia and therapeutic perspectives

  2019cites this paper
• Emerging approaches to target mitochondrial apoptosis in cancer cells

  2019influential citation
• Emerging treatment options for patients with p53-pathway-deficient CLL

  2019cites this paper
• Emerging DNA methylation inhibitors for cancer therapy: challenges and prospects

  2019cites this paper
• Recent advances in chronic lymphocytic leukemia therapy

  2019cites this paper
• Targeting the Bcl-2 Family in B Cell Lymphoma

  2019cites this paper
• Gene-Specific Targeting of DNA Methylation in the Mammalian Genome

  2019cites this paper
• Promoter Methylation Status of Survival-Related Genes in MOLT- 4 Cells Co-Cultured with Bone Marrow Mesenchymal Stem Cells under Hypoxic Conditions

  2018cites this paper
• NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib

  2018cites this paper
• BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

  2018cites this paper
• Targeting Mitochondrial Ion Channels to Fight Cancer

  2018cites this paper
• DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status

  2018cites this paper
• Potential of BCL2 as a target for chronic lymphocytic leukemia treatment

  2018cites this paper
• Targeting BCL-2 in Hematologic Malignancies

  2018cites this paper
• Frontline Therapy of CLL: Evolving Treatment Paradigm

  2018cites this paper
• Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia.

  2018cites this paper
• The Usual Suspects in Melanoma Pathogenesis and the Role of Tissue Microarrays Analysis in Melanoma Research

  2018cites this paper
• Characterisation of polyunsaturated fatty acid synthesis in peripheral blood mononuclear cells

  2018cites this paper
• Venetoclax: Targeting BCL2 in Hematological Cancers.

  2018cites this paper
• The role of the genetic abnormalities, epigenetic and microRNA in the prognosis of chronic lymphocytic leukemia.

  2018cites this paper
• Non-coding RNAs, epigenetics, and cancer: tying it all together

  2018cites this paper
• From Basic Knowledge to Effective Therapies.

  2018cites this paper
• Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma

  2018cites this paper
• Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.

  2018cites this paper
• BCL2 (B-Cell Leukemia/Lymphoma 2)

  2018cites this paper
• Modulatory role of betulinic acid in N-nitrosodimethylamine-induced hepatorenal toxicity in male Wistar rats

  2017cites this paper
• Epigenetic drivers of tumourigenesis and cancer metastasis.

  2017cites this paper
• Diferenciación plasmocelular en linfomas no-Hodgkin de células B: implicaciones clínicas y terapéuticas

  2017cites this paper
• Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances.

  2017cites this paper
• Nodal marginal zone lymphoma. An emerging entity

  2017cites this paper